Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
25 studies found for:    Tysabri | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Tysabri
2 Not yet recruiting Immunogenicity and Safety Study of Natalizumab (BG00002) Administered to Participants With Relapsing Multiple Sclerosis
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: BG00002 (natalizumab)
3 Not yet recruiting Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract
Condition: Graft Versus Host Disease
Interventions: Drug: Natalizumab;   Drug: Methylprednisolone
4 Not yet recruiting Natalizumab (BG00002) as an Efficacy Switch in Subjects With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies
Condition: Relapsing Multiple Sclerosis
Intervention: Drug: Natalizumab
5 Recruiting PK and PD Study of Natalizumab in Pediatric Subjects With RRMS
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention: Biological: Natalizumab
6 Recruiting CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Condition: Crohn's Disease
Intervention: Drug: Natalizumab
7 Not yet recruiting Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease
Condition: Acute Graft Versus Host Disease
Interventions: Drug: natalizumab;   Drug: steroids
8 Not yet recruiting Real-world Outcomes on Tecfidera® (BG00012, Dimethyl Fumarate) Post-Tysabri® (BG00002, Natalizumab)
Condition: Relapsing-Remitting Multiple Sclerosis
Interventions: Biological: BG00002 (Natalizumab);   Drug: BG00012 (dimethyl fumarate)
9 Recruiting The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Tysabri ® (Natalizumab)
10 Recruiting TOP: IMA-06-02 Tysabri® Observational Program
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention:
11 Recruiting Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
12 Recruiting Ireland Natalizumab (TYSABRI®) Observational Program
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention:
13 Recruiting Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod
Condition: Relapsing Remitting Multiple Sclerosis
Intervention:
14 Unknown  Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab
Conditions: Multiple Sclerosis;   Cognitive Impairment
Intervention:
15 Not yet recruiting Alternative Treatment Paradigm for Natalizumab Trial
Condition: Multiple Sclerosis (MS)
Intervention: Drug: methylprednisolone
16 Recruiting Impact Study of 2 Therapeutic Strategy for Aggressive Remitting Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Other: mitoxantrone - immunomodulator;   Other: natalizumab
17 Recruiting Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide
Condition: Multiple Sclerosis
Intervention: Drug: teriflunomide
18 Recruiting Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention:
19 Recruiting Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Condition: Acute Ischemic Stroke
Interventions: Biological: BG00002 (Natalizumab);   Drug: Placebo
20 Recruiting Observational Study of Tysabri® in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus (JCV) Antibody Negative Participants
Condition: Relapsing-Remitting Multiple Sclerosis
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years